Skip to main content
Figure 6 | Malaria Journal

Figure 6

From: Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP142) administered intramuscularly with adjuvant system AS01

Figure 6

Allele specific antibody titres to 50 μg MSP1 42 (FVO)/AS01 vs 50 μg MSP1 42 (3D7)/AS02 post third immunization. Comparison of MSP142 allele specific antibody responses induced by immunization with 50 μg MSP142 3D7/AS02 and MSP142 FVO/AS01. Log ELISA OD 1.0 titres are reported as the median and 25 and 75% quartile antibody response. Hatched boxes indicate the antigen specific antibody responses induced by the MSP142 3D7/AS02 vaccine, a study conducted at WRAIR in 2001 (reference 7), and open boxes indicate the responses induced by the MSP142 FVO/AS01 vaccine. Plate antigens were the WRAIR E. coli expressed recombinant proteins, MSP142 3D7, FVO and CAMP alleles. P values are calculated from two-tailed t-tests.

Back to article page